ResMed (RMD) announced impressive Q3 2025 earnings with a strong revenue of $1.3 billion, winning praises and confidence from different financial analysts. KeyBanc, Piper Sandler, and RBC Capital have all reacted positively, showing increased confidence in RMD's stocks. The company reported above-estimate revenues and profits and also declared a quarterly dividend of $0.53. They continue to extend their market dominance in sleep solutions as sales from their sleep devices demonstrated solid demand. Historically, RMD has shown impressive EPS growth which was due to tariff exemptions. A fresh highlight in RMD's journey is the appointment of a renowned finance expert Salli Schwartz, from Illumina, as the Chief Investor Relations Officer. The company has also recently launched the NightOwl device, an innovative solution to simplify home sleep apnea testing across the US. Despite slight economic concerns, RMD's Q3 financial performance, coupled with strategic investments, have excited the market. The company's shares rose by 11.28% on April 24th. However, some analysts believe the stock price is undervalued and suggest the intrinsic value could be 32% higher.
Resmed RMD News Analytics from Thu, 24 Oct 2024 07:00:00 GMT to Sat, 26 Apr 2025 22:09:01 GMT -
Rating 8
- Innovation 7
- Information 9
- Rumor -3
